{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-028183","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.813894+00:00","generated_at":"2026-06-12T00:12:56.574283+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sangamo Q2 net loss $114.5M, revenue down 77% YoY; impairments of $51.3M","bullets":["Net loss $114.5M ($0.66/sh) vs $43.2M ($0.29/sh) YoY, driven by $51.3M intangible asset impairment.","Revenue $6.8M vs $29.4M YoY, down 77% due to terminations of Novartis, Biogen, Sanofi deals.","Total GAAP op expenses $130.4M (incl. $51.3M impairment); non-GAAP op expenses $72.3M.","Cash & marketable securities $182.1M at June 30; raised $15.1M via ATM; cash runway >12 months.","Updated 2023 GAAP op expense guidance $378-398M; non-GAAP unchanged at $240-260M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-028183","json":"https://secwatch.observer/filing/0001628280-23-028183.json","markdown":"https://secwatch.observer/filing/0001628280-23-028183.md","text":"https://secwatch.observer/filing/0001628280-23-028183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023028183/0001628280-23-028183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828023028183/sgmo-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:12:56.574283+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}